Those aiming for above-average market returns often engage in the meticulous process of stock picking. Choosing the right stocks can make a substantial difference in your wealth.
Hims & Hers Health Inc (NYSE: HIMS) closed the day trading at $57.7 down -0.21% from the previous closing price of $57.82. In other words, the price has decreased by -$0.21 from its previous closing price. On the day, 18.6 million shares were traded. HIMS stock price reached its highest trading level at $58.94 during the session, while it also had its lowest trading level at $56.43.
Ratios:
For a better understanding of HIMS, let’s look at its different ratios. It provided that stocks Price–to–Cash (P/C) ratio for the trailing twelve months (TTM) is standing at 11.39 whereas its Price-to-Free Cash Flow (P/FCF) for the term is 111.97. For the most recent quarter (mrq), Quick Ratio is recorded 4.46 and its Current Ratio is at 4.98. In the meantime, Its Debt-to-Equity ratio is 1.86 whereas as Long-Term Debt/Eq ratio is at 1.85.
On June 04, 2025, Needham reiterated its Buy rating and also lowered its target price recommendation from $61 to $65. TD Cowen Downgraded its Buy to Hold on April 29, 2025, while the target price for the stock was maintained at $30.
Insider Transactions:
The insider trade also gives investors a glimpse into the future direction of stock prices, which can be beneficial to investors. A recent insider transaction in this stock occurred on Sep 22 ’25 when Oluyemi Okupe bought 154,958 shares for $57.70 per share.
Boughton Soleil sold 2,637 shares of HIMS for $133,168 on Sep 17 ’25. The Chief Legal Officer now owns 166,404 shares after completing the transaction at $50.50 per share. On Sep 17 ’25, another insider, Carroll Patrick Harrison, who serves as the Chief Medical Officer of the company, sold 10,021 shares for $50.50 each. As a result, the insider received 506,060 and left with 169,940 shares of the company.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, HIMS now has a Market Capitalization of 13041330176 and an Enterprise Value of 12941103104. As of this moment, Hims’s Price-to-Earnings (P/E) ratio for their current fiscal year is 72.22, and their Forward P/E ratio for the next fiscal year is 73.07. The expected Price-to-Earnings-to-Growth (PEG) calculation for the next 5 years is 2.84. For the stock, the TTM Price-to-Sale (P/S) ratio is 6.48 while its Price-to-Book (P/B) ratio in mrq is 23.15. Its current Enterprise Value per Revenue stands at 6.427 whereas that against EBITDA is 80.804.
Stock Price History:
The Beta on a monthly basis for HIMS is 2.25, which has changed by 2.341054 over the last 52 weeks, in comparison to a change of 0.1675967 over the same period for the S&P500. Over the past 52 weeks, HIMS has reached a high of $72.98, while it has fallen to a 52-week low of $15.73. The 50-Day Moving Average of the stock is 13.10%, while the 200-Day Moving Average is calculated to be 34.79%.
Shares Statistics:
Over the past 3-months, HIMS traded about 35.73M shares per day on average, while over the past 10 days, HIMS traded about 31780660 shares per day. A total of 217.38M shares are outstanding, with a floating share count of 202.54M. Insiders hold about 10.39% of the company’s shares, while institutions hold 77.75% stake in the company. Shares short for HIMS as of 1756425600 were 74635929 with a Short Ratio of 2.09, compared to 1753920000 on 64593744. Therefore, it implies a Short% of Shares Outstanding of 74635929 and a Short% of Float of 40.919998.
Earnings Estimates
The current market rating for Hims & Hers Health Inc (HIMS) reflects the collective analysis of 5.0 analysts closely monitoring its performance.The consensus estimate for the next quarter is $0.26, with high estimates of $0.31 and low estimates of $0.17.
Analysts are recommending an EPS of between $1.24 and $0.78 for the fiscal current year, implying an average EPS of $1.07. EPS for the following year is $1.38, with 5.0 analysts recommending between $1.77 and $0.99.
Revenue Estimates
12 analysts predict $578.99M in revenue for the current quarter. It ranges from a high estimate of $590.87M to a low estimate of $567.56M. As of the current estimate, Hims & Hers Health Inc’s year-ago sales were $401.56MFor the next quarter, 12 analysts are estimating revenue of $629.41M. There is a high estimate of $685.04M for the next quarter, whereas the lowest estimate is $592.7M.
A total of 14 analysts have provided revenue estimates for HIMS’s current fiscal year. The highest revenue estimate was $2.41B, while the lowest revenue estimate was $2.3B, resulting in an average revenue estimate of $2.34B. In the same quarter a year ago, actual revenue was $1.48BBased on 13 analysts’ estimates, the company’s revenue will be $2.8B in the next fiscal year. The high estimate is $3B and the low estimate is $2.5B.
